GEJ |
gastric/esophagogastric junction |
CRC |
colorectal cancer |
EC |
esophageal cancer |
GC |
gastric cancer |
ESCC |
esophageal squamous cell carcinoma |
SCC |
esophageal adenocarcinoma |
CRT |
chemoradiotherapy |
TNM |
tumor node metastasis |
CAR-T |
chimeric antigen receptor-therapy |
EGFR2 |
epidermal growth factor receptor 2 |
TAMs |
tumor-associated macrophages |
IFN |
interferon |
IL |
interleukin |
TCR |
T cell receptor |
BCR |
B cell receptor |
MHC |
major histocompatibility complex |
NK cell |
natural killer cell |
DCs |
dendritic cells |
CTLA-4 |
cytotoxic T-lymphocyte-associated protein 4 |
LAG-3 |
lymphocyte activation gene 3 |
ASCO |
American Society of Clinical Oncology |
TIM-3 |
T cell immunoglobulin 3 |
PD-1 |
programmed cell death 1 |
PD-L1 |
programmed cell death ligand 1 |
ACT |
adoptive cell therapy |
NKT cell |
natural killer T cell |
IDO |
indoleamine 2,3-dioxygenase |
MSI |
microsatellite instability |
MSS |
microsatellite stability |
dMMR |
defective match repair |
pMMR |
proficient match repair |
ORR |
objective response rate |
EBV |
Epstein-Barr virus |
APC |
antigen-presenting cell |
CMS 1-4 |
consensus molecular subtype 1-4 |
TGF-β |
transforming growth factor β |
TNF-α |
tumor necrosis factor α |
GM-CSF |
granulocyte-macrophage colony stimulating factor |
Mst1 |
macrophage stimulator 1 |
CCL2/CCR2 |
C-C motif chemokine ligand 2/C-C motif chemokine ligand 2 receptor |
CSF1R |
colony stimulating factor-1 receptor |
KIRs |
killer-cell immunoglobulin-like receptors |
NKG2A |
CD94/NK group 2 member A |
HLA |
leukocyte antigen |
TME |
tumor microenvironment |
TIME |
tumor immune microenvironment |
MDSCs |
myeloid derived suppressor cells |
CDR3 |
complementarity determining region 3 |
ADCP |
antibody-dependent cellular phagocytosis |
CEA |
carcino-embryonic antigen |
HER2 |
human epidermal growth factor receptor-2 |
GPC3 |
complement C3 protein |
EpCAM |
epithelial cell adhesion molecule |
EGFR |
epidermal growth factor receptor |
VEGF |
vascular endothelial growth factor |
SIRPα |
signal regulatory protein-α |
PLR |
platelet-lymphocyte ratio |
TAP2 |
ATP binding cassette subfamily B member 3 |
ICI |
immune checkpoint inhibitor therapy |
ECM |
extracellular matrix |
TILs |
tumor infiltrating lymphocytes |
CAFs |
cancer-associated fibroblasts |
EGF |
epidermal growth factor |
Breg cells |
regulatory B cells |
Treg cells |
regulatory T cells |
RCC |
renal cell carcinoma |
CEA |
carcinoembryonic antigen |
ROS |
reactive oxygen species |
RNS |
reactive nitrogen species |
MMP9 |
matrix metalloproteinase 9 |
NETs |
neutrophil extracellular traps |
MSI-H |
microsatellite instability-high |
iNKT cells |
invariant natural killer T cells |
PFS |
progression-free survival |
OS |
overall survival |